Reported 4 days ago
Viking Therapeutics, whose stock surged 116% last year, faces significant challenges this year with a 40% decline in value. Despite promising drug candidates like VK2735 and VK2809 showing potential in weight loss and liver disease treatment, uncertainties around drug approvals and competition in the GLP-1 market loom large. While there’s potential for substantial revenue growth, Viking's future status among top healthcare stocks will depend on developing a diverse pipeline of successful products.
Source: YAHOO